The pharmacokinetics of nortriptyline in patients with chronic renal failure.

1 The pharmacokinetics of single oral doses of nortriptyline were studied in twenty patients with chronic renal failure, eight of whom were receiving treatment with haemodialysis. 2 The median nortriptyline half-life was 25.2 h (range 14.5-140.0 h) and the median nortriptyline clearance was 32.3 l/h (range 8.1-122.0 l/h). 3 No differences were observed between the dialysed and non-dialysed groups. 4 Comparisons of nortriptyline half-life and clearance between the patients and groups of physically healthy subjects revealed no significant differences. 5 There was no significant linear correlation between age and either of these measurements. In the twelve patients not receiving haemodialysis there was no correlation between nortriptyline clearance and glomerular filtration rate. 6 Chronic renal failure is not associated with a significant alteration in nortriptyline metabolism as measured by its half-life or clearance, but the drug should nonetheless be used with caution, and monitored whenever possible. However, the marked inter-individual differences observed in nortriptyline half-life and clearance in patients with chronic renal failure may not be solely responsible for their unpredictable response to tricyclic antidepressant therapy, and other possible contributory factors are discussed.

[1]  H. R. Tyler,et al.  Neurologic disorders in renal failure. , 1968, The American journal of medicine.

[2]  J. Court,et al.  Psychological aspects of the management of chronic renal failure. , 1968, British medical journal.

[3]  D. Azarnoff,et al.  Plasma protein binding of tricyclic anti-depressants in man. , 1969, Biochemical pharmacology.

[4]  M. Åsberg,et al.  Relationship between Plasma Level and Therapeutic Effect of Nortriptyline , 1971, British medical journal.

[5]  Prevalence of chronic renal failure and access to dialysis. , 1973, International journal of epidemiology.

[6]  M. Åsberg.  Plasma nortriptyline levels—relationship to clinical effects , 1974, Clinical pharmacology and therapeutics.

[7]  L. Gram,et al.  First‐pass metabolism of nortriptyline in man , 1975, Clinical pharmacology and therapeutics.

[8]  M. Reidenberg.  The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. , 1977, The American journal of medicine.

[9]  M. Reidenberg.  The biotransformation of drugs in renal failure. , 1977, The American journal of medicine.

[10]  G. Levy,et al.  Pharmacokinetics in renal disease. , 1977, The American journal of medicine.

[11]  D. Buchanan,et al.  Psychosis and Pseudo Dementia Associated with Hemodialysis , 1978, International journal of psychiatry in medicine.

[12]  J. Biggs,et al.  Nortriptyline Plasma Levels and Subjective Side Effects* , 1978, British Journal of Psychiatry.

[13]  R. Braithwaite,et al.  Nortriptyline in depressed patients with high plasma levels. II , 1978, Clinical pharmacology and therapeutics.

[14]  R. Braithwaite,et al.  Simplified method for monitoring tricyclic antidepressant therapy using gas--liquid chromatography with nitrogen detection. , 1978, Journal of chromatography.

[15]  L. Bertilsson,et al.  Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. , 1979, Life sciences.

[16]  F. Goodwin,et al.  Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. , 1979, Biological psychiatry.

[17]  S. Snowden,et al.  The prevalence of psychiatric illness among patients on home haemodialysis , 1979, Psychological Medicine.

[18]  R. Braithwaite,et al.  Dosage Adjustment from Simple Nortriptyline Spot Level Predictor Tests in Depressed Patients , 1979, Clinical pharmacokinetics.

[19]  R. Braithwaite,et al.  Pharmacokinetics of Single Oral Doses of Nortriptyline in Depressed Elderly Hospital Patients and Young Healthy Volunteers , 1980, Clinical pharmacokinetics.